Table 3.
Clinical characteristics of the nine patients who accepted osimertinib after abivertinib
| Abivertinib | Osimertinib | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No. | Age/Sex | Dose | Response | PFS (months) | Reasons for withdrawal | Site of progression | Response | Progression (Yes/No) | PFS (months) | OS (months) |
| 1 | 68M | 300 mg bid | SD‡ | 2.8 | ILD | — | PR | Yes | 12.0 | 18.9 |
| 2 | 72F | 300 mg bid | NA | 0.8 | Skin rash | — | PR | No | 15.0 | 29.8† |
| 3 | 63M | 300 mg bid | PR | 4.3 | Private reason | — | PR | Yes | 9.0 | 19.4 |
| 4 | 56M | 300 mg bid | PR | 6.9 | Progression | CNS, Lung§ | PR | Yes | 9.0 | 26.6 |
| 5 | 61F | 300 mg bid | PR | 4.0 | Progression | CNS | SD | No | 17.0 | 28.2† |
| 6 | 71F | 300 mg bid | PD | 2.9 | Progression | CNS, Lung, Liver | PD | Yes | 1.0 | 4.9 |
| 7 | 39F | 300 mg bid | PD | 1.2 | Progression | Lung | PR | No | 10.0 | 19.2† |
| 8 | 62M | 300 mg bid | PD | 2.8 | Progression | Lung | SD | Yes | 5.0 | 15.7 |
| 9 | 31M | 300 mg bid | PR | 5.7 | Progression | Lung | PR | No | 12.0 | 17.8† |
†
Patients who were alive at end date.
‡
Not confirmed.
§
Patient accepted brain radiotherapy after progression occurred in the CNS.